由ECARX控股公司提交。

根据1933年《证券法》第425条，

经修订并视为依据规则14a-12提交

根据修订后的1934年《证券交易法》

主题公司：Cova Acquisition Corp.

委托文号：001-40012

战略投资协议

本战略投资协议(《协议》)于2022年5月26日由在开曼群岛注册成立的获豁免有限责任公司ECARX控股有限公司(“发行人”)和根据英属维尔京群岛法律注册成立的吉利投资控股有限公司签订。(“投资者”)。本协议中使用和未定义的大写术语的含义与交易协议(定义如下)中此类术语的含义相同。

鉴于， 本协议是与截至本协议日期的特定协议和合并计划(可根据其条款，“交易协议”而不时修订、修改、补充或放弃)签订的，由发行人、Cova Acquisition Corp.(一家在开曼群岛注册成立的获豁免有限责任公司(“SPAC”))、Ecarx Temp Limited(一家在开曼群岛注册成立的获豁免有限责任公司)和发行人的直接全资子公司(“合并附属公司1”)签订。及Ecarx&Co Limited，一家于开曼群岛注册成立的获豁免有限责任公司及发行人的直接全资附属公司(“合并附属公司2”)，根据该等协议，(A)合并附属公司1将与SPAC合并并并入SPAC(“首次合并”)，而SPAC为首次合并中尚存的公司，并于首次合并生效后成为发行人的全资附属公司。和(B)SPAC将与第二次合并合并(“第二次合并”)并合并为第二次合并(“交易”)， 与第一次合并和交易协议中设想的其他交易(“交易”)， 第二次合并中的幸存公司合并第二次合并后，成为发行人的全资子公司；

鉴于，鉴于与交易有关并视交易完成而定，投资者希望认购和购买，发行人 希望在交易结束日向投资者发行和出售发行人2,000,000股A类普通股，每股面值$0.000005 ，每股收购价10美元(“每股收购价”)， 总收购价20,000,000美元(“认购额”)，所有这些都是按照本协议规定的条款和条件进行的；以及

鉴于与交易有关，发行人和/或SPAC(A)将于本交易日期签订认购协议，并可能在本交易日期后与某些投资者(“其他股权投资者”，与投资者合称“股权投资者”)签订后续股权认购协议(连同于本交易日期签订的认购协议， “股权认购协议”)，据此，其他股权投资者已同意或将同意认购和购买，且发行人已同意或将同意于截止日期按每股购买价格向其他股权投资者发行及出售股份，及(B)发行人可与若干各方(各自为“融资方”及“融资方”合称“融资方”)订立若干准许融资协议(除股权认购协议外)，据此，发行人可同意 向该等融资方发行发行人的股权证券。

因此，现在，考虑到前述以及双方的陈述、保证和契诺，在符合本协议所载条件并打算在此受法律约束的情况下，双方特此协议如下：

吉利投资控股有限公司。

收件人： 马步青

电子邮件：buqing.ma@geely.com

将所需的副本(该副本不构成通知) 发送给：

浙江吉利控股(集团)有限公司。

收信人： 黄帝华

电子邮件：tihua.Huang@geely.com

东方航空滨江中心2座16楼东方航空控股有限公司

龙栏路277号

上海市徐汇区200041

中华人民共和国
注意：Tony Chen
邮箱：tony.chen@ecarxgroup.com

将所需的副本(不构成通知)发送给：

Skadden，Arps，Slate，Meagher&Flom LLP
中国世界办公室2号30楼

建国门外大道1号

北京100004，中国
注意：Peter X.Huang，Esq.
电子邮件：peter.ang@skadden.com

[签名页如下]

在此，投资者已签署或促使其正式授权代表签署本协议，证明日期为以上所述日期。

[战略投资协议签字页]

发行人已签署或促使其正式授权的代表于上述日期签署本协议，特此为证。

有关该交易的其他重要信息将向美国证券交易委员会备案。

关于拟议的交易，ECARX控股公司(“ECARX”) 将向美国证券交易委员会(“美国证券交易委员会”)提交一份F-4表格的注册说明书，其中将包括 将与拟议的交易相关发行的ECARX证券的招股说明书，以及一份关于Cova Acquisition Corp.(“Cova”)股东大会的委托书，以对拟议的交易进行投票。鼓励Cova的股东和其他相关方阅读初步委托书/招股说明书以及将提交给美国证券交易委员会的其他 文件，因为这些文件将包含有关Cova和ECARX以及拟议交易的重要信息。 在登记声明宣布生效后，将包括在登记声明中的最终委托书/招股说明书将邮寄给Cova的股东，以建立对拟议交易的投票记录日期。一旦获得，Cova的股东 还将能够免费获得F-4的副本，包括委托书/招股说明书和其他提交给美国证券交易委员会的文件 ，方法是将请求发送到：Cova Acquisition Corp.，530 Bush Street，Suite703 San Francisco，California 94108。将包含在注册说明书中的初步和最终委托书/招股说明书一旦准备好，也可以在美国证券交易委员会的网站(www.sec.gov)免费获得。

征集活动的参与者

根据美国证券交易委员会的规则，Cova和ECARX及其各自的董事和高管 可被视为本通信中描述的潜在交易的委托书征集的参与者 。有关Cova董事和高管及其所有权的信息，请参阅Cova提交给美国证券交易委员会的文件。根据美国证券交易委员会的规则，哪些人可能被视为参与Cova股东对潜在交易的征集，有关这些人的其他信息，将在提交给美国证券交易委员会的包含初步委托书/招股说明书的登记声明 中阐述。这些文件可在美国证券交易委员会网站www.sec.gov免费获取，或直接向Cova Acquisition Corp.提出请求，地址为加利福尼亚州旧金山布什街530号，Suite703，邮编：94108。

没有要约或恳求

本通信不是代表的声明或邀请，也不是对任何证券或潜在交易的同意或授权，也不构成 出售要约或邀请购买Cova或ECARX的任何证券，也不会在任何州或司法管辖区进行任何此类证券的出售，在根据该州或司法管辖区的证券法律注册或资格登记或资格之前，此类证券的出售将是非法的。除非招股说明书符合经修订的1933年《证券法》(以下简称《证券法》)的要求，否则不得提出证券要约。

前瞻性陈述

本新闻稿包含《证券法》第27A节和经修订的1934年《证券交易法》第21E节含义的前瞻性陈述，这些陈述基于信念和 假设以及Cova和ECARX目前可用的信息。

All statements other than statements of historical fact contained in this communication are forward-looking statements. In some cases, you can identify forward-looking statements by the following words: “may,” “will,” “could,” “would,” “should,” “expect,” “intend,” “plan,” “anticipate,” “believe,” “estimate,” “predict,” “project,” “potential,” “continue,” “ongoing,” “target,” “seek” or the negative or plural of these words, or other similar expressions that are predictions or indicate future events or prospects, although not all forward-looking statements contain these words. These statements are based upon estimates and forecasts and reflect the views, assumptions, expectations, and opinions of COVA and ECARX, which involve risks, uncertainties and other factors that may cause actual results, levels of activity, performance or achievements to be materially different from those expressed or implied by these forward-looking statements. Any such estimates, assumptions, expectations, forecasts, views or opinions, whether or not identified in this communication, should be regarded as preliminary and for illustrative purposes only and should not be relied upon as being necessarily indicative of future results. Although each of COVA and ECARX believes that it has a reasonable basis for each forward-looking statement contained in this communication, each of COVA and ECARX caution you that these statements are based on a combination of facts and factors currently known and projections of the future, which are inherently uncertain. In addition, there will be risks and uncertainties described in the proxy statement/prospectus on Form F-4 relating to the proposed transaction, which is expected to be filed by ECARX with the SEC and other documents filed by COVA or ECARX from time to time with the SEC. These filings may identify and address other important risks and uncertainties that could cause actual events and results to differ materially from those expressed or implied in the forward-looking statements. Neither COVA nor ECARX can assure you that the forward-looking statements in this communication will prove to be accurate. These forward-looking statements are subject to a number of risks and uncertainties, including the ability to complete the business combination due to the failure to obtain approval from COVA shareholders or satisfy other closing conditions in the merger agreement, the occurrence of any event that could give rise to the termination of the merger agreement, the ability to recognize the anticipated benefits of the business combination, the amount of redemption requests made by COVA public shareholders, costs related to the transaction, the impact of the global COVID-19 pandemic, the risk that the transaction disrupts current plans and operations as a result of the announcement and consummation of the transaction, the outcome of any potential litigation, government or regulatory proceedings and other risks and uncertainties, including those to be included under the heading “Risk Factors” in the registration statement on Form F-4 to be filed by ECARX with the SEC and those included under the heading “Risk Factors” in the final prospectus of COVA dated February 4, 2021 and in its subsequent filings with the SEC. In light of the significant uncertainties in these forward-looking statements, you should not regard these statements as a representation or warranty by COVA or ECARX, their respective directors, officers or employees or any other person that COVA or ECARX will achieve their objectives and plans in any specified time frame, or at all. The forward-looking statements in this communication represent the views of COVA and ECARX as of the date of this communication. Subsequent events and developments may cause those views to change. However, while COVA and ECARX may update these forward-looking statements in the future, COVA and ECARX specifically disclaim any obligation to do so, except to the extent required by applicable law. You should, therefore, not rely on these forward-looking statements as representing the views of COVA and ECARX as of any date subsequent to the date of this communication. Accordingly, undue reliance should not be placed upon the forward-looking statements.